Irbesartan Tarbis Farma

Irbesartan, the active ingredient in Irbesartan Tarbis Farma, is an Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is employed to treat hypertension and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring products are shipped with appropriate documentation and temperature control where required, guaranteeing consistent product integrity.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function.

- Hypertension: reduces systolic and diastolic blood pressure, helping to control high blood pressure. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes, preserving renal function. - Proteinuria: decreases urinary protein excretion in diabetic patients, contributing to renal protection.

Irbesartan may cause adverse reactions, ranging from common, mild events to rare, serious conditions.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Upper respiratory infection: symptoms such as sore throat or nasal congestion. - Hyperkalemia: elevated potassium levels, often mild.

Serious or Rare Side Effects: - Angioedema: rapid swelling of the face, lips, tongue, or throat, potentially life‑threatening. - Renal impairment: worsening kidney function, indicated by rising creatinine. - Severe hyperkalemia: markedly high potassium that can affect heart rhythm. - Hypotension: significant drop in blood pressure causing faintness. - Hepatic injury: abnormal liver enzymes or liver dysfunction.

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure patient safety.

- Monitor blood pressure: check regularly to avoid excessive hypotension. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Use caution in pregnancy: avoid use in the second and third trimesters due to potential fetal harm. - Avoid in severe hepatic impairment: dose adjustment may be necessary. - Store at ambient temperature: keep in the original pack, protect from moisture.

Irbesartan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use raises the risk of angioedema and renal impairment. - NSAIDs: can diminish renal protective effects and increase the chance of kidney injury.

Moderate Interactions (Monitor Closely): - Diuretics: additive hypotensive effect may require dose adjustment. - Lithium: Irbesartan may raise lithium concentrations, necessitating monitoring. - Cyclosporine: may increase serum creatinine, indicating reduced kidney function. - Rifampin: can lower Irbesartan plasma levels, potentially reducing efficacy.